Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

40,991 stories, page 415 of 684

Advanced search

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

EIFO invests DKK 20m in biotech firm Quantumcell

medwatch.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

IPO News - IPO Winners & Losers: Jersey Mike's, Bubble Baths, and Biotech Wins

renaissancecapital.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Ensuring drug quality: mastering stability testing in pharma

European Pharmaceutical ReviewOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Lexicon's HCM study spans 20 countries; results anticipated Q1 2027

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

The Manila TimesOriginal source

🇪🇺Jul 27Researchmyesr.orgTier 2 · Direct publisher

Imaging Saves Lives: Report from the European Parliament event on the role of imaging in improving cardiovascular health

European Society of RadiologyOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Lexicon completes enrollment in phase 3 heart disease trial By Investing.com

Investing.com CanadaOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Medicus Pharma Receives FDA 'Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

The Manila TimesOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Compounded GLP-1 drugs creating concern among doctors and FDA

NewsNationOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

Quiver QuantitativeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome

The Manila TimesOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Medicus Pharma Receives FDA “Study May Proceed” Letter for

GlobeNewswireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice matters

Mail & GuardianOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA Escalates Warnings Over Unregulated Compounded GLP-1 Weight Loss Drugs

streamlinefeed.co.keOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy

Clinical LeaderOriginal source

🇨🇦Jul 27Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Sphere-9™ Catheter

There have been forty-six (46) reported incident reports (none of which were from Canada) where pati...

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 27Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Spacelabs Healthcare Xhibit® Central Station

Spacelabs Healthcare has concluded that the use of the previously distributed splitter (part number...

Health Canada Recalls and Safety AlertsOriginal source

🇨🇦Jul 27Regulatoryrecalls-rappels.canada.caTier 1 · Regulatory source

Harmonic Arts Holy Basil Tincture; Out of Specification (total aerobic microbial count)

The total aerobic microbial count is out of specification in the affected lot.

Health Canada Recalls and Safety AlertsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Asia-Pacific Roundup: TGA adopts 23 international scientific guidelines

RAPSOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

GlobeNewswireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Science Spotlight: Taking the Leap to Found a Biotech Startup

CUNY Graduate CenterOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Oak Hill Bio and Research Alliance Corporation III Announce

GlobeNewswireOriginal source

🇺🇸Jul 27CROir.labcorp.comTier 3 · Secondary coverage

Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing

Labcorp Drug DevelopmentOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?

Yahoo FinanceOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA panel backs six peptides for pharmacy compounding

Manufacturing ChemistOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Eikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLC

Quiver QuantitativeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Wockhardt Gets US FDA Approval for Novel Antibiotic Zaynich

WhalesbookOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

The Manila TimesOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Eikon Doses First Patient in EIK1001 Stage 4 Lung Cancer Study

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Business WireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

PR NewswireOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It

Yahoo FinanceOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice

TradingViewOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Legend Biotech (LEGN) Announces CEO Transition with Interim Leadership

GuruFocusOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb

Quiver QuantitativeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma plans 111-patient Phase 3 corneal pain trial

Stock TitanOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

BNP Paribas Adjusts PT on West Pharmaceutical Services to $459 From $447, Maintains Outperform Rating

marketscreener.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Weiss Asset Management LP Invests $1.99 Million in West Pharmaceutical Services, Inc. $WST

MarketBeatOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B

Endpoints NewsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Leadership Changes at Legend Biotech (LEGN)

GuruFocusOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma

Quiver QuantitativeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Legend Biotech CEO Ying Huang Resigns

marketscreener.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Kolon TissueGene Executives Buy Shares After Clinical Trial Failure, Signaling Confidence

finance.biggo.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Amazon Filters eyes global pharma market at record-breaking ISPE Singapore 2026

Cleanroom TechnologyOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Magazine: Made in the USA

Pharmaceutical TechnologyOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

HBM Holdings Enters Strategic Collaboration With China National Pharmaceutical Group On Biologics Research And Development

TradingViewOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

FDA approves first OTC acetaminophen-naproxen fixed-dose combination

Manufacturing ChemistOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

CSPC Pharmaceutical Expects H1 2026 Profit Attributable RMB5.9 Bln–RMB6.2 Bln

TradingViewOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

pharmaphorumOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

CSPC Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2026D Stable Sales Growth

marketscreener.comOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Thyroid medication described as 'subpotent drug' recalled by FDA

WUSA9Original source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

Pharmaceutical TechnologyOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%

RTTNewsOriginal source

🇺🇸Jul 27Industrybambusatx.comTier 1 · Company source

Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential

Bambusa TherapeuticsOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Legend Biotech Announces CEO Transition, Appoints Alan Bash Interim Chief Executive Officer

Quiver QuantitativeOriginal source

🌍Jul 27discoverynews.google.comTier 3 · Aggregated media

Legend Biotech CEO Ying Huang steps down, Alan Bash named interim

Investing.comOriginal source

🌍Jul 27discoverynews.google.comTier 2 · Trade media

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

Fierce BiotechOriginal source